ClinicalTrials.gg
Sign In
RecruitingNCT07879755Updated Oct 19, 2026

An Extension Trial of GW 906 in Participants With Essential Hypertension

An interventional study of GW906 in Hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Sep 2026).
  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 19, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906

Read the detailed description

This is an open-label, multicenter, non-randomized, long term extension study. Total study duration is expected to be up to 2 years, with a maximum of 3 years. Participants who have completed the previous GW906 Injection study will be assessed for eligibility at the screening visit of this study. Those who meet the eligibility criteria will receive the first dose of the extension treatment. Participants enrolled in this study will be preferentially assigned to Cohort 1. After enrollment into Cohort 2 has been initiated, participants will be assigned to receive treatment of the Cohort 2.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • siRNA
  • GW906
  • SAL0132
03

In context

Hypertension

6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 90 across 5,095 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd. is the lead sponsor of 41 studies on the registry; 17 are open to participants now.

Browse Shenzhen Salubris Pharmaceuticals Co., Ltd. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed study treatment and the study in accordance with the protocol for GW906 injection.
  • Willing to participate in the study and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension.
  • Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; International normalized ratio (INR) > 2.0; Serum potassium > 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2.
  • History of any cardiovascular event within 6 months.
  • Patients with active malignancy or a history of malignancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    GW906

    Subcutaneous injection. Expected to be up to 2 years

    Drug: GW906

Interventions

  • DrugGW906

    Subcutaneous injection. Expected to be up to 2 years

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to treatment discontinuation

    An adverse event (AE) is any untoward medical occurrence in a participant administered with investigational medicinal product, which may manifest as signs, symptoms, disease, or abnormal laboratory findings

    Time frame: every 3 month, up to 3 years

Secondary outcomes

  1. Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit

    Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit

    Time frame: Baseline, Weeks 4, 12, 24, up to 3 years

07

Study locations

1 of 1 sites recruiting
  • Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
    Shanghai, Shanghai Municipality 200025, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

Of 94 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 58. This study's planned 31 months is close to that.

Counting every sponsor, half of 1,433 studies reached it within 23 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 19, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Jan 30, 2029
CompletionEst.
Jan 30, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07879755
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Jun 12, 2026
Primary completion
Jan 30, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Jiguang Wang, Professor
Contact
jiguangwang@rjh.com.cn
+86-13764189476

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GW906

Other studies in this condition

Hypertension →

Other studies from this sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd. →

Start the discussion